Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Viteri

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Revista Espanola De Medicina Nuclear E Imagen Molecular|March 6, 2021
Immunotherapy, cancer and PETM Simó-Perdigó, J L Vercher-Conejero, S Viteri, et al.
Radiologia|April 3, 2007
[Mammographic findings in microcalcifications associated with breast cancer after neoadjuvant chemotherapy]J J Noguera, E de Luis, A Alonso-Burgos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 3, 2007
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumabM González Cao, S Viteri, C Garrán, et al.
Revista De Medicina De La Universidad De Navarra|September 25, 2007
[Small-cell lung cancer]J L Pérez-Gracia, J M López-Picazo, S Martín-Algarra, et al.
Oncology|June 10, 2008
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanomaM González-Cao, S Viteri, A Díaz-Lagares, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLCD Rodríguez-Abreu, M Cobo, S García-Román, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisionsC Mayo-de-Las-Casas, N Jordana-Ariza, M Garzón-Ibañez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Revista Espanola De Medicina Nuclear E Imagen Molecular|March 6, 2021
Immunotherapy, cancer and PETM Simó-Perdigó, J L Vercher-Conejero, S Viteri, et al.
Radiologia|April 3, 2007
[Mammographic findings in microcalcifications associated with breast cancer after neoadjuvant chemotherapy]J J Noguera, E de Luis, A Alonso-Burgos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 3, 2007
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumabM González Cao, S Viteri, C Garrán, et al.
Revista De Medicina De La Universidad De Navarra|September 25, 2007
[Small-cell lung cancer]J L Pérez-Gracia, J M López-Picazo, S Martín-Algarra, et al.
Oncology|June 10, 2008
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanomaM González-Cao, S Viteri, A Díaz-Lagares, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLCD Rodríguez-Abreu, M Cobo, S García-Román, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisionsC Mayo-de-Las-Casas, N Jordana-Ariza, M Garzón-Ibañez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 1